Royalty Pharma Gross Profit 2019-2024 | RPRX

  • Royalty Pharma annual gross profit for 2024 was $2.264B, a 3.86% decline from 2023.
  • Royalty Pharma annual gross profit for 2023 was $2.355B, a 5.24% increase from 2022.
  • Royalty Pharma annual gross profit for 2022 was $2.237B, a 2.28% decline from 2021.

Historical Chart (TTM)

Click on chart icon to view chart
Click on table icon to view table

Quarterly

Click on chart icon to view chart
Click on table icon to view table

Quarterly - YOY Change

Click on chart icon to view chart
Click on table icon to view table

Annual

Click on chart icon to view chart
Click on table icon to view table

Annual % Change

Click on chart icon to view chart
Click on table icon to view table
Related Stocks
Company NameMarket
Cap
American Express (AXP)$217.7B
Blackstone (BX)$120.5B
Moody's (MCO)$93.5B
Coinbase Global (COIN)$64.8B
Brookfield Asset Management (BAM)$26.9B
Synchrony Financial (SYF)$25.5B
Orix Corp Ads (IX)$24.6B
SoFi Technologies (SOFI)$17.6B
Equitable Holdings (EQH)$17.4B
Jefferies Financial Group (JEF)$14.3B
BB Seguridade Participacoes SA (BBSEY)$14B
Houlihan Lokey (HLI)$12.8B
Globe Life (GL)$10.4B
Daiwa Securities Group (DSEEY)$9.8B
Freedom Holding (FRHC)$9.5B
Brookfield Wealth Solutions (BNT)$8.8B
XP (XP)$8.1B
SouthState (SSB)$7.8B
Upstart Holdings (UPST)$7.8B
StepStone Group (STEP)$7.3B
Rithm Capital (RITM)$6.2B
Blue Owl Capital (OBDC)$6.1B
Lazard (LAZ)$6.1B
Virtu Financial (VIRT)$5.9B
Euronet Worldwide (EEFT)$4.8B
PJT Partners (PJT)$4.2B
AXOS FINANCIAL, INC (AX)$4B
StoneX Group (SNEX)$4B
Intercorp Financial Services (IFS)$3.7B
Abrdn (SLFPY)$3.6B